Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$1.19
+0.01 (+1.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-72.0M · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$37M
P/E
N/A
•EV/EBITDA
N/A
•ROE
73.2%
↑Gross Margin
74.5%
↑Debt/Equity
-1.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-8974.3%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $642000.0 · net income $-69.9M · FCF $-57.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $642000.00 | $642000.00 | $2.3M | $1.4M | $375000.00 | — | — | — | — | — |
| Net Income | $-69.9M | $-69.9M | $-59.6M | $-179.1M | $-165.8M | $-106.9M | $-82.2M | $-33.0M | $-19.3M | $-4.5M |
| EBITDA | $-52.6M | $-52.6M | $-44.2M | $-165.4M | $-157.2M | $-106.6M | $-82.1M | $-33.4M | $-19.9M | $-4.5M |
| EPS | -5.73 | -5.73 | -23.51 | -98.40 | -94.72 | -64.80 | -60.64 | — | — | — |
| Gross Margin | 74.5% | 74.5% | 5.4% | 8.7% | 94.7% | — | — | — | — | — |
| Operating Margin | -7829.8% | -7829.8% | -2859.8% | -12146.3% | -42572.0% | — | — | — | — | — |
| Net Margin | -10887.4% | -10887.4% | -2630.1% | -12974.9% | -44201.9% | — | — | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | -1.15 | -1.15 | -1.10 | -1.79 | 1.22 | — | — | — | — | — |
| Current Ratio | 0.62 | 0.62 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-57.6M | $-57.6M | $-72.0M | $-155.0M | $-135.5M | $-82.6M | $-66.7M | $-28.0M | $-13.8M | — |
| Returns | ||||||||||
| ROE | 73.2% | 73.2% | 64.0% | 316.9% | -215.9% | -48.2% | -39.8% | -122.6% | -49.6% | 462.2% |
| Valuation | ||||||||||
| P/B | — | — | — | — | 8.21 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | -71.7% | -71.7% | 64.2% | 268.0% | — | — | — | — | — | — |
| EPS Growth | 75.6% | 75.6% | 76.1% | -3.9% | — | -6.9% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-23.51 → -5.73
Residual
+0.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.